Phathom Pharmaceuticals announced that its new drug application for VOQUEZNA has been accepted for filing by the FDA, with a target action date of July 19, 2024. The company plans to initiate an additional Phase 3 study for an investigational As Needed treatment for heartburn relief in adults with Non-Erosive GERD.